Comparison between Roche and Xpert in HIV-1 RNA quantitation: A high concordance between the two techniques except for a CRF02_AG subtype variant with high viral load titters detected by Roche but undetected by Xpert

Journal of Clinical Virology

Volumn 93, Issue , 2017, Pages 15-19

  Avidor, Boaz ^a,b   Matus, Natalia ^a,b   Girshengorn, Shirley ^a,b   Achsanov, Svetlana ^a,b   Gielman, Simona ^a,b   Zeldis, Irene ^a,b   Schweitzer, Inbal ^a,b   Adler, Amos ^b   Turner, Dan ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

HIV clinical laboratory; HIV 1 viral load monitoring; HIV 1 viral load tests

Indexed keywords

RNA; VIRUS RNA;

ARTICLE; CLINICAL ASSESSMENT TOOL; COMPARATIVE STUDY; FALSE NEGATIVE RESULT; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; HIV RAPID TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF QUANTITATION; LONG TERMINAL REPEAT; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRAL LOAD TESTING; VIRUS DETECTION; VIRUS LOAD; BLOOD; CONSENSUS SEQUENCE; DNA SEQUENCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF DETECTION; MOLECULAR DIAGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS GENE;

BASE SEQUENCE; CONSENSUS SEQUENCE; GENES, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LIMIT OF DETECTION; MOLECULAR DIAGNOSTIC TECHNIQUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 85019672739     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2017.05.014     Document Type: Article

References (37)

1. Gunthard, H.F., Saag, M.S., Benson, C.A., et al. Antiretroviral drugs for treatment and prevention of HIV infections in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA 316 (2016), 191–210.
2. World Health Organization Guidelines, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing Hiv Infection. Chapter 4: Clinical Guidelines: Antiretroviral Therapy. Second edition. 2016, World Health Organization Guidelines, Geneva, Switzerland Accessed 22 December 2016. Available at: www.who.int/hiv/pub/arv/arv-2016/en.
3. Waters, L., Ahmed, N., Angus, B., et al. British HIV Association Guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2015 (2016 interim update). Chapter 7: Managing virological failure, 2016 www.bhiva.org/guidelines.aspx. Accessed at: 26 December 2016.
4. European AIDS Clinical Society Guidelines, Version 8.1, October 2016. Part II: ART of HIV-1 positive persons. 2016 Available at: www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines. Accessed 26 December 2016.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2016, Department of Health and Human Services Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 26 December 2016. Page H1.
6. World Health Organization Global Health Sector Response to HIV, 2000–2015: focus on innovations in Africa, a progress report. Available at: http://www.who.int/hiv/pub/progressreports/2015-progress-report/en/. Accessed 26 December 2016.
7. UNAIDS 90-90-90 an Ambitious Treatment Target to Help End the AIDS Epidemic. 2014. Available at: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed 1 November 2015.
8. Peter, T., Ellenberger, D., Kim, A.A., et al. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infect. Dis. 17 (2017), e26–e29.
9. Moyo, S., Mohammed, T., Wirth, K.E., et al. Point-of care Cepheid Xpert HIV-1 viral load test in rural African communities is feasible and reliable. J. Clin. Microbiol. 54 (2016), 3050–3055, 10.1128/JCM. 01594-16.
10. Jordan, J.A., Plantier, J.C., Templeton, K., et al. Multi-site clinical evaluation of the Xpert HIV-1 viral load assay. J. Clin. Virol. 80 (2016), 27–32.
11. Gueudin, M., Baron, A., Allesandri-Gradt, E., Leme'e, V., et al. Performance evaluation of the new HIV-1 quantification assay Xpert HIV-1 viral load, on a wide panel of HIV-1 variants. J. Acuir. Immune Defic. Syndr. 72 (2016), 521–526.
12. Ehret, R., Schutze, M., Moritz, A., et al. Performance of the Cepheid Xpert HIV-1 VL compared to the Abbott RealTime HIV-1 viral load measurement. 25th European Congress of Clinical Microbiology and Infectious Diseases Abstract P0567, 25–28 April 2015 Copenhagen, Denmark, 2016.
13. Ceffa, S., Luhanga, R., Andreotti, M., et al. Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. J. Virol. Methods 229 (2016), 35–39.
14. Mor, O., Gozlan, Y., Wax, M., et al. Evaluation of the real-time HIV-1, and Aptima HIV-1 Quant Dx assays in comparison to the NucliSens EasyQ HIV-1 v2.0 assay for quantitation of HIV-1 viral load. J. Clin. Microbiol. 53 (2015), 3458–3465.
15. Bruzzone, B., Caligiuri, P., Nigron, N., et al. In response to Gueudin et al: Xpert HIV-1 viral load assay and VERSANT HIV-1 RNA 1.5 assay, a performance comparison. JAIDS 74 (2017), e86–e88, 10.1097/QAI.000000000000127.
16. Ouma, B., Crocomble, L., Salha, J., et al. Presentation at ESCV 2015: poster 2 abstract N 1621: evaluation of the clinical performance of the Xpert HIV-1 viral load assay, Abstract. J. Clin. Virol. 70 (2015), S1–S126.
17. Garrett, N.J., Drain, P.K., Amsunder, N., et al. Diagnostic accuracy of the point-of-care Xpert HIV-1 viral load assay in a South African HIV clinic. J. Acquir. Immune Defic. Syndr. 72 (2016), e45–e48.
18. Avidor, B., Turner, D., Mor, Z., et al. Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. PLoS One, 8, 2013, e57789.
19. Avidor, B., Girshengorn, S., Matus, N., et al. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. J. Clin. Microbiol. 51 (2013), 880–886.
20. Sollis, K.A., Smit, P.W., Fiscus, S., et al. Systematic review of performance of HIV viral load technologies on plasma samples. PLoS One, 9, 2014, e85869.
21. Senechal, B., James, V.L.A., Ten years of xternal quality assessment of human immunodeficiency virus type 1 RNA quantitation. J. Clin. Microbiol. 50 (2012), 3614–3619.
22. Bourlet, T.A., Signori-Schmuck, L., Roche, L., et al. HIV-1 load comparison using four commercial real-time assays. J. Clin. Microbiol. 49 (2011), 292–297.
23. Church, D., Gregson, D., Lloyd, T., et al. Comparison of the real-time HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J. Clin. Microbiol. 49 (2011), 118–124.
24. Los Alamos HIV sequence database. Distribution of HIV-1 sequences: World. Available at: http://www.hiv.lanl.gov/.
25. Heipertz, R.A. Jr., Ayemoba, O., Path, F.M.C., et al. Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG. Medicine, 95(August (32)), 2016 e4346.
26. Hemalaar, J., Gouws, E., Ghys, P.D., et al. Global trends in epidemiology of HIV-1 during 2000–2007. AIDS, 2011, 679–689.
27. Amendola, A., Marsella, P., Bloisi, M., et al. Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2.0) to quantify low HIV-1 RNA levels (<1000 copies/milliliter): comparison with clinical samples and NISBC working reagent for nucleic acid testing assays. J. Clin. Microbiol. 52 (2014), 2019–2026.
28. Hopkins, M., Hau, S., Tiernan, C., et al. Comparative performance of the new aptima HIV-1 Quant Dx assay with three commercial PCR-based HIV-1 RNA quantitation assays. J. Clin. Virol. 69 (2015), 56–62.
29. Margariti, A., Chatzidimitriou, D., Metallidis, S., et al. Comparing Abbott m2000 RealTime HIV test and Roche Cobas Ampliprep/Ciobas Taqman HIV test, v2.0 in treated HIV-1B and non-B subjects with low viremia. J. Med. Virol. 88 (2016), 724–727.
30. Briggs, R., Templeton, K., Fenando, I., Comparing HIV viral load assays and frequency of low level virological rebound in clinical practice. Int. J. STD AIDS 25 (2014), 1029–1034.
31. Yan, C.S., Hanafi, I., Kelleher, A.D., et al. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantitation. J. Clin. Virol. 49 (2010), 249–253.
32. Mourez, T., Delaugerre, C., Vray, M., et al. Comparison of the BioMe'rieux NucliSens EasyQ v2.0-HIV-1 RNA quantitation assay versus Abbott RealTime HIV-1 and Roche Cobas TaqMan HIV-1 v2.0 on current epidemic HIV-1 variants. J. Clin. Virol. 71 (2015), 76–81.
33. Ndiaye, O., Diop-Ndiaye, H., Ouedraogo, A.S., et al. Comparison of four commercial viral load techniques in an area of non-B HIV-1 subtype circulation. J. Virol. Methods 222:20150 (2016), 122–131.
34. Gomes, P., Carvalho, A.P., Diogo, I., et al. Comparison of NucliSENS EasyQ HIV-1 v2.0 with Abbott m2000rt RealTime HIV-1 assay for plasma RNA quantitation in different HIV-1 subtypes. J. Virol. Methods 193 (2013), 18–22.
35. Tatarelli, P., Taramasso, L., Di Biagio, A., et al. HIV-1 RNA quantitation in CRF02_AG HIV-1 infection: too easy to make mistakes. New Microbiol. 39 (2016), 150–152.
36. Damond, F., Avettand-Fenoel, V., Collin, G., et al. Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantitation. J. Clin. Microbiol. 48 (2010), 1413–1416.
37. Shah, K., Viswanath, V., Saga, A., et al. High sensitivity detection of HIV-1 using two genomic targets compared with single target PCR. J. Med. Virol. 88 (2016), 1092–1097.